Literature DB >> 16814948

First-year PSA kinetics and minima after prostate cancer radiotherapy are predictive of overall survival.

Rex Cheung1, Susan L Tucker, Deborah A Kuban.   

Abstract

PURPOSE: We analyzed whether first-year prostate-specific antigen (PSA) kinetics and minima are predictive of overall survival (OS). METHODS AND MATERIALS: The data set contained 1,174 patients treated with external beam radiotherapy (RT) from 1987 to 2001. The relative rate of change (lambda) in post-RT PSA values during the first year (13.5 months) was computed using regression analysis of ln(PSA) vs. time. We also computed the PSA minimum (mPSA) reached during the same period. Recursive partitioning analysis was used to identify the relevant cutpoints for the factors being investigated for its association with survival: age, pretreatment PSA, radiation dose, relative rate of change in PSA post-RT, and 1-year PSA minimum. For each of the other factors stage, Gleason score and risk group, all possible cutpoints were considered in the multivariate analyses. Significant factors were considered in the multivariate analyses to identify independent predictors for overall survival.
RESULTS: The median value of lambda was -1.0 years(-1) (range, -11.0-5.1 years(-1)). The 1-year minimum had a median of 0.8 ng/mL (range, 0.01-30.9 ng/mL). Recursive partitioning analysis and Cox proportional hazards analyses identified the following pretreatment or treatment factors adversely related to OS: age, Gleason score, stage, and dose. First-year mPSA > or = 4 ng/mL and lambda > 0 were post-RT independent prognostic factors for worse OS.
CONCLUSION: First-year post-RT PSA kinetics and minima are early response parameters predictive of overall survival for prostate cancer patients. These factors may be useful in selecting patients for early salvage therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16814948     DOI: 10.1016/j.ijrobp.2006.04.028

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  6 in total

1.  Mechanistic modelling of prostate-specific antigen dynamics shows potential for personalized prediction of radiation therapy outcome.

Authors:  Guillermo Lorenzo; Víctor M Pérez-García; Alfonso Mariño; Luis A Pérez-Romasanta; Alessandro Reali; Hector Gomez
Journal:  J R Soc Interface       Date:  2019-08-14       Impact factor: 4.118

2.  Predicting biochemical failure and overall survival through intratherapy PSA changes during definitive external beam radiotherapy.

Authors:  Daniel E Soto; Rebecca R Andridge; Jeremy M G Taylor; Patrick W McLaughlin; Howard M Sandler; Charlie C Pan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-05-19       Impact factor: 7.038

3.  Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir.

Authors:  Mekhail Anwar; Vivian Weinberg; Albert J Chang; I-Chow Hsu; Mack Roach; Alexander Gottschalk
Journal:  Radiat Oncol       Date:  2014-02-02       Impact factor: 3.481

4.  Significant impact of biochemical recurrence on overall mortality in patients with high-risk prostate cancer after carbon-ion radiotherapy combined with androgen deprivation therapy.

Authors:  Goro Kasuya; Hitoshi Ishikawa; Hiroshi Tsuji; Takuma Nomiya; Hirokazu Makishima; Tadashi Kamada; Koichiro Akakura; Hiroyoshi Suzuki; Jun Shimazaki; Yasuo Haruyama; Gen Kobashi; Hirohiko Tsujii
Journal:  Cancer       Date:  2016-06-28       Impact factor: 6.860

5.  Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost as post-external beam radiotherapy versus conventionally fractionated external beam radiotherapy for localized prostate cancer.

Authors:  Jeong Hoon Phak; Hun Jung Kim; Woo Chul Kim
Journal:  Prostate Int       Date:  2015-12-12

6.  Parameters predicting for prostate specific antigen response rates at one year post low-dose-rate intraoperative prostate brachytherapy.

Authors:  Kevin Martell; Tyler Meyer; Michael Sia; Steve Angyalfi; Siraj Husain
Journal:  J Contemp Brachytherapy       Date:  2017-04-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.